dc.contributor.authors |
Bilir, C; Yildiz, I; Bilici, A; Ucar, M; Berk, V; Yildiz, Y; Yazici, O; Imamoglu, GI; Karadurmus, N; Pilanci, KN; Arpaci, E; Tanriverdi, O; Karci, E; Temiz, S; Nayir, E; Oktay, E; Dal, P; Petekkaya, I; Varim, C; Cinemre, H; |
|
dc.date.accessioned |
2020-02-27T08:26:51Z |
|
dc.date.available |
2020-02-27T08:26:51Z |
|
dc.date.issued |
2017 |
|
dc.identifier.citation |
Bilir, C; Yildiz, I; Bilici, A; Ucar, M; Berk, V; Yildiz, Y; Yazici, O; Imamoglu, GI; Karadurmus, N; Pilanci, KN; Arpaci, E; Tanriverdi, O; Karci, E; Temiz, S; Nayir, E; Oktay, E; Dal, P; Petekkaya, I; Varim, C; Cinemre, H; (2017). Is Change in Hemoglobin Level a Predictive Biomarker of Tyrosine Kinase Efficacy in Metastatic Renal Cell Carcinoma? A Turkish Oncology Group Study. CANCER INVESTIGATION, 35, 255-248 |
|
dc.identifier.issn |
0735-7907 |
|
dc.identifier.uri |
https://doi.org/10.1080/07357907.2017.1292518 |
|
dc.identifier.uri |
https://hdl.handle.net/20.500.12619/65884 |
|
dc.description.abstract |
Background: There are insufficient predictive markers for renal cell carcinoma (RCC). Methods: A total of 308 metastatic RCC patients were analyzed retrospectively. Results: The increased hemoglobin (Hb) group had significantly higher progression-free survival and overall survival (OS) compared with the decreased Hb group at 11.5 versus 6.35months (p < .001) and 21.0 versus 11.36months (p < .001) respectively. The 1- and 3-year OS rates were higher in the Hb increased group, i.e., 84% versus 64% and 52% versus 35% respectively. Conclusions: The present study showed that increased Hb levels after tyrosine kinase inhibitor therapy could be a predictive marker of RCC. |
|
dc.language |
English |
|
dc.publisher |
TAYLOR & FRANCIS INC |
|
dc.subject |
Oncology |
|
dc.title |
Is Change in Hemoglobin Level a Predictive Biomarker of Tyrosine Kinase Efficacy in Metastatic Renal Cell Carcinoma? A Turkish Oncology Group Study |
|
dc.type |
Article |
|
dc.identifier.volume |
35 |
|
dc.identifier.startpage |
248 |
|
dc.identifier.endpage |
255 |
|
dc.contributor.department |
Sakarya Üniversitesi/Tıp Fakültesi/Dahili Tıp Bilimleri Bölümü |
|
dc.contributor.saüauthor |
Bilir, Cemil |
|
dc.contributor.saüauthor |
Varım, Ceyhun |
|
dc.contributor.saüauthor |
Cinemre, Hakan |
|
dc.relation.journal |
CANCER INVESTIGATION |
|
dc.identifier.wos |
WOS:000399505100004 |
|
dc.identifier.doi |
10.1080/07357907.2017.1292518 |
|
dc.identifier.eissn |
1532-4192 |
|
dc.contributor.author |
Bilir, Cemil |
|
dc.contributor.author |
Ibrahim Yildiz |
|
dc.contributor.author |
Ahmet Bilici |
|
dc.contributor.author |
Mahmut Ucar |
|
dc.contributor.author |
Veli Berk |
|
dc.contributor.author |
Yasar Yildiz |
|
dc.contributor.author |
Ozan Yazici |
|
dc.contributor.author |
Goksen Inanc Imamoglu |
|
dc.contributor.author |
Nuri Karadurmus |
|
dc.contributor.author |
Kezban Nur Pilanci |
|
dc.contributor.author |
Erkan Arpaci |
|
dc.contributor.author |
Ozgur Tanriverdi |
|
dc.contributor.author |
Ebru Karci |
|
dc.contributor.author |
Suleyman Temiz |
|
dc.contributor.author |
Erdinc Nayir |
|
dc.contributor.author |
Esin Oktay |
|
dc.contributor.author |
Pinar Dal |
|
dc.contributor.author |
Ibrahim Petekkaya |
|
dc.contributor.author |
Varım, Ceyhun |
|
dc.contributor.author |
Cinemre, Hakan |
|